Compares two insulins in pregnant women with diabetes
Compares insulin detemir and NPH insulin in pregnant women with diabetes.
Key facts
- Who runs it
- University of California, Los Angeles
- Where
- Los Angeles, United StatesSee the site
- Trial code
- Registry title
- DETERMINE: Detemir vs NPH
- Status
- Recruiting
- Phase
- Phase 2
- People taking part
- 336 people, planned
- Started
- 1 Feb 2022
- Planned end
- Jun 2025
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Insulin Detemir
- Insulin NPH
- Record updated
- 26 September 2023
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for pregnant women with type 2 diabetes or gestational diabetes who need insulin. It compares two long-acting insulins, detemir and NPH.
- Age
- 18 years or older
- Sex
- All sexes (pregnant women)
- Disease stage
- Pregnant, with type 2 diabetes that was there before pregnancy or gestational diabetes, and needing insulin for blood sugar control
- Earlier treatment
- Cannot have needed insulin before becoming pregnant
Main reasons for not taking part
- Twin or other multiple pregnancy
- Type 1 diabetes
- Known allergy to NPH or insulin detemir
- Known major fetal malformations
- Known HIV, hepatitis B or hepatitis C
This trial only enrols pregnant participants. The registry sentence this rests on: Inclusion criteria will include pregnant women with pre-existing T2DM and GDM who requiring insulin to manage their blood sugars in pregnancy.
The registry criteria, word for word
Show all 10 criteriaShow less
Who can take part
- Inclusion criteria will include pregnant women with pre-existing T2DM and GDM who requiring insulin to manage their blood sugars in pregnancy
Who cannot take part
- Indication for planned premature delivery (placenta accrete, or prior classical cesarean delivery)
- Type 1 Diabetes mellatus
- Known or suspected hypersensitivity to NPH or insulin detemir
- Chronic renal or hepatic insufficiency
- Known to be HIV, Hepatitis B, or Hepatitis C positive
- Age < 18
- Multiple Gestation
- Known fetal major malformations
- Insulin dependent before conception
Where in United States
- University of California, Los AngelesLos Angeles, United StatesContact: Christina S Han, MDTaking people
About the trial
What the trial wants to find out
The purpose of the study is to compare rates of neonatal hypoglycemia with maternal NPH vs determir use.
The 2 groups in the trial
- Insulin DetemirTreatment being tested
Patients are to receive insulin detemir as long acting insulin to control blood sugars
- Insulin NPHExisting treatment, for comparison
Patients are to receive insulin NPH as long acting insulin to control blood sugars
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Phase 2 Open Label Randomized Controlled Trial Determir Vs Neutral Protamine Hagedorn (NPH) In Pregnant Women: DETERMINE Study
- Plain-language title
- Compares two insulins in pregnant women with diabetesGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 26 September 2023